Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: a Randomized Prospective Study in 202 Patients with Superficial Bladder Cancer
Overview
Authors
Affiliations
We report the second interim analysis of data from a randomized prospective trial comparing the prophylactic effect of 15 courses of 50 mg. doxorubicin, 50 mg. thiotepa or 150 mg. bacillus Calmette-Guerin instilled intravesically against recurrences and progression of superficial transitional cell bladder cancer. Of 202 enrolled patients 176 currently are evaluable with a mean follow-up of 3 years (range 3 to 97 months). The number of patients with recurrences was significantly lower in the bacillus Calmette-Guerin arm (9 of 67) compared to the doxorubicin (23 of 53, p equals 0.002) and thiotepa (20 of 56, p equals 0.003) arms. The over-all recurrence index per 100 patient-months also was lower for the bacillus Calmette-Guerin versus the thiotepa and doxorubicin groups (0.53 versus 1.55 and 1.7, respectively). Bacillus Calmette-Guerin also was superior in preventing recurrences and progression of high risk tumors, that is stage T1, grade 3 or multiple growths, associated or not with carcinoma in situ. In the stage T1 category 19 of 32 (60%) tumors recurred under treatment with doxorubicin, 11 of 33 (33%) with thiotepa and 6 of 49 (12%) with bacillus Calmette-Guerin. Toxicity to intravesical bacillus Calmette-Guerin was higher compared to the other drugs but it was not limiting: bladder irritability and malaise occurred in 42% of the patients, granulomatous cystitis in 16.4% and bladder contraction in 1.4% (1 of 64). The latter complication occurred in a patient whose stage T1m grade 2 tumors had recurred 3 times, who underwent 3 transurethral bladder resections within 15 months and who had received thiotepa for 4 months after having been removed from the study 11 months after entry. Three patients in the doxorubicin group (5.6%) underwent radical cystectomy for local urothelial progression. One patient (1.8%) in the same group died of distant progression. Our preliminary results suggest that at the dose, periodicity and duration used in the study bacillus Calmette-Guerin is significantly superior to the chemotherapeutic agents doxorubicin and thiotepa for the prophylaxis of recurrence and retardation of progression in superficial transitional cell bladder tumors.
Ostrowski D, Chelluri R, Herzig M, Xia L, Cortese B, Roberson D Cancers (Basel). 2023; 15(14).
PMID: 37509407 PMC: 10377836. DOI: 10.3390/cancers15143746.
Del Giudice F, Asero V, Bologna E, Scornajenghi C, Carino D, Dolci V Cancers (Basel). 2023; 15(7).
PMID: 37046598 PMC: 10093360. DOI: 10.3390/cancers15071937.
Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context.
Liu Y, Niu L, Li N, Wang Y, Liu M, Su X Adv Sci (Weinh). 2023; 10(12):e2205641.
PMID: 36908053 PMC: 10131876. DOI: 10.1002/advs.202205641.
Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma.
Doroud D, Hozouri H Iran Biomed J. 2022; 26(5):340-9.
PMID: 36369747 PMC: 9763876. DOI: 10.52547/ibj.3676.
Jin Y, Zeng X, Liu T, Bai Z, Dou Z, Ding D Mil Med Res. 2022; 9(1):44.
PMID: 35978389 PMC: 9382792. DOI: 10.1186/s40779-022-00406-y.